B-cell Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for B-cell Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-07-18Clinical Trial Update: A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) [Phase 1]
Phase 1 study evaluating ABO2203, an mRNA-encoded CD19/CD3 T cell engager, in patients with relapsed or refractory B-cell non-Hodgkin lympho…
-
CLINICAL_TRIALS research · 2025-07-16Clinical Trial Update: A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 clinical study evaluating CT1194C in relapsed/refractory B-cell non-Hodgkin lymphoma is listed as not yet recruiting.
-
CLINICAL_TRIALS research · 2025-07-08Clinical Trial Update: JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia [NA]
A clinical trial update for JY231 injection in relapsed or refractory B-cell lymphomas and leukemias, currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-07-01Clinical Trial Update: CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) [Phase 1]
Phase 1 study update for CD19 CAR-allogeneic NKT therapy (ANCHOR) in relapsed or refractory B-cell malignancies; the trial is currently acti…
-
CLINICAL_TRIALS research · 2025-07-01Clinical Trial Update: CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies [Phase 1]
Mayo Clinic is conducting a Phase 1 clinical trial evaluating a CD19-directed CAR-T cell therapy for relapsed/refractory B-cell malignancies…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-06-23Clinical Trial Update: A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 ) [Phase 1]
A Phase 1 clinical study evaluating CT1190B (CT1190B-CG1101) in relapsed/refractory B-cell non-Hodgkin lymphoma; the trial is currently not …
-
CLINICAL_TRIALS research · 2025-06-10Clinical Trial Update: JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia [NA]
This clinical trial update indicates that JY231 injection is being studied for relapsed/refractory B-cell acute lymphoblastic leukemia and B…
-
CLINICAL_TRIALS research · 2025-06-09Clinical Trial Update: A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas [Phase 1]
This clinical trial update reports that ATG-031 is being studied in a Phase 1 trial for patients with advanced solid tumors or B-cell non-Ho…
-
CLINICAL_TRIALS research · 2025-06-03Clinical Trial Update: One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL [NA]
Recruitment is ongoing for JCXH-213 to evaluate its safety, tolerability, and efficacy in patients with recurrent or refractory B-cell non-H…
-
CLINICAL_TRIALS trial_result · 2025-05-29Clinical Trial Update: Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial of magrolimab in combination with rituximab (with or without chemotherapy) in relapsed/refractory B-cell non-Hodgkin lymphom…
-
CLINICAL_TRIALS trial_result · 2025-05-28Clinical Trial Update: Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1) [Phase 1]
This update reports Phase 1 safety findings for MB-CART2019.1 in patients with B-cell non-Hodgkin lymphoma.
-
CLINICAL_TRIALS research · 2025-05-25Clinical Trial Update: TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating TRAC and SPPL3 gene-knockout allogeneic CD19-targeting CAR-T cells for relapsed/refractory B-cell non-…
-
CLINICAL_TRIALS trial_result · 2025-05-23Clinical Trial Update: A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma [Phase 1]
This update notes the completion of a Phase 1 study evaluating C-CAR039 in subjects with relapsed/refractory B-cell non-Hodgkin lymphoma.
-
CLINICAL_TRIALS research · 2025-05-22Clinical Trial Update: A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance [Phase 1, Phase 2]
A Phase 1/2 study of blinatumomab in patients with Pre-B cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma as remission main…
-
CLINICAL_TRIALS trial_result · 2025-05-15Clinical Trial Update: Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) [Phase 1]
Phase 1 study assessing feasibility and safety of UCD19 CD19-directed CAR T cells in adults with relapsed/refractory B-cell non-Hodgkin lymp…
-
CLINICAL_TRIALS trial_result · 2025-05-15Clinical Trial Update: JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia [NA]
A clinical trial update indicates that JY231 injections are being studied for relapsed/refractory B-cell acute lymphoblastic leukemia and B-…
-
CLINICAL_TRIALS trial_result · 2025-04-29Clinical Trial Update: Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma [Phase 1]
Phase 1 clinical trial evaluating pentostatin, bendamustine, and ofatumumab for chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma…
-
CLINICAL_TRIALS trial_result · 2025-04-17Clinical Trial Update: Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma [Phase 1]
Phase 1 study of PCLX-001 in relapsed/refractory advanced solid tumors and B-cell non-Hodgkin lymphoma has completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2025-04-16Clinical Trial Update: A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas [Phase 1, Phase 2]
Clinical trial update on a Phase I/II study evaluating the safety of autologous CD20 CAR-T cells in relapsed or refractory B-cell non-Hodgki…
-
CLINICAL_TRIALS trial_result · 2025-04-09Clinical Trial Update: HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 study of HMPL-760 in relapsed/refractory B-cell non-Hodgkin lymphoma has completed.
-
CLINICAL_TRIALS research · 2025-04-06Clinical Trial Update: Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies [Phase 1]
A Phase 1 clinical trial update evaluating the safety and efficacy of DuoCAR20.19.22-D95 in adults with relapsed or refractory B-cell malign…
-
CLINICAL_TRIALS research · 2025-03-25Clinical Trial Update: Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma [Phase 1]
A Phase Ib trial evaluating Rocbrutinib in combination with R-CHOP for newly diagnosed B-cell Non-Hodgkin Lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2025-03-25Clinical Trial Update: A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies [Phase 1]
A Phase 1 clinical trial of RS001 in relapsed/refractory B-cell malignancies, including B-cell Non-Hodgkin's Lymphoma and Acute Lymphoblasti…
-
CLINICAL_TRIALS trial_result · 2025-03-25Clinical Trial Update: A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 clinical trial of LUCAR-20SP in relapsed or refractory B-cell non-Hodgkin lymphoma is currently recruiting at a Chinese cancer cen…
-
CLINICAL_TRIALS research · 2025-03-24Clinical Trial Update: CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) [Phase 1]
A Phase 1 trial evaluating a CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy (ANTLER) for relapsed/refractory B-cell non-Hodgkin lymph…